Table of ContentsIntroductionRead (pg. 5)Pharma Deals & Trends: M&A, Licensing, and R&D EvolutionRead (pg. 6)MethodologyRead (pg. 7)GSK and 35PharmaRead (pg. 8)GSK and RAPT TherapeuticsRead (pg. 9)Pfizer and NovavaxRead (pg. 10)Gilead Sciences and ArcellxRead (pg. 11)Eli Lilly and Company and Innovent Biologics, Inc.Read (pg. 12)Pfizer and Sciwind BiosciencesRead (pg. 13)Madrigal Pharmaceuticals and Suzhou Ribo Life Science, Ribocure Pharmaceuticals Read (pg. 14)AbbVie and RemeGenRead (pg. 15)Sanofi and Dynavax Technologies CorporationRead (pg. 16)AstraZeneca and CSPC PharmaceuticalsRead (pg. 17)Major Pharmaceutical Deals in 2026Read (pg. 18)Pharma Deals in Focus: Therapeutic Areas and Drug Class TrendsRead (pg. 19)Investment and fundingRead (pg. 20)ConclusionRead (pg. 21)ReferencesRead (pg. 24)Pharma Insight Reportshttps://adisinsight.springer.com/insight-hub